Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic Hepatitis B initially treated with tenofovir disoproxil: A retrospective observational survey

Basit Öğe Kaydı
dc.authorid0000-0003-2419-3436en_US
dc.contributor.authorKalkan, İrem Akdemir
dc.contributor.authorKaraşahin, Ömer
dc.contributor.authorSarıgül, Figen
dc.contributor.authorToplu, Sibel Altunışık
dc.contributor.authorAladağ, Murat
dc.contributor.authorAkgül, Fethiye
dc.contributor.authorDemir, Yakup
dc.contributor.authorÇelen, Mustafa Kemal
dc.date.accessioned2023-03-21T13:13:57Z
dc.date.available2023-03-21T13:13:57Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: In chronic hepatitis B patients with or exposed to the risk of osteoporosis or renal dysfunction, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) or entecavir (ETV) maybe the right choice. Objectives: This study aimed to present real-life data in terms of the efficacy and safety of a TAF/ETV treatment change while receiving TDF. Methods: This retrospective study was conducted on 344 adult patients from 10 centers. The data of patients who had changed to ETV (n = 107) and TAF (n = 237) while receiving TDF were analyzed. The data collected at 0 and 6 months of treatment were analyzed. The virological response was assessed based on undetected hepatitis B virus (HBV) DNA. Serum alanine aminotransferase (ALT) values were used to evaluate the biochemical response. For renal function, serum creatinine and phosphorus, as well as estimated glomerular filtration rate (eGFR), were recorded. Moreover, lumbar spine and hip T-scores along with the serum lipid profile were evaluated. Results: The mean age of patients was 41.14 +/- 13.46 years, and 224 (65.1%) of the participants were male. The treatment arms were not significantly different in terms of demographic characteristics, comorbid diseases, infection duration, family history of HBV infection, blood platelet count, serum biomarkers, such as ALT, phosphorus, creatinine, total bilirubin, albumin, lipid profile, and HBV DNA levels at the beginning. No statistically significant difference was found between the proportion of undetectable HBV DNA of the two treatment groups after 6 months (P = 0.221). The ALT normalization in the ETV and TAF groups at the sixth month compared to the baseline levels was not significantly different (P = 0.853, P = 0.330, respectively). There was no statistically significant difference between the two treatment arms regarding changes in eGFR, creatinine, phosphorus, hip, and spine T-scores from baseline to 6 months (P = 0.296, P = 0.78, P = 0.141, P = 0.832, P = 0.947, respectively). In those who switched to TAF or ETV, low-density lipoproteins cholesterol were observed to be significantly higher after 6 months compared to baseline values (P = 0.002, P = 0.049, respectively). The TC increased significantly in the TAF group (P = 0.035). Conclusions: Our study showed that switching to ETV and TAF sustained the viral suppression and biochemical response achieved by TDF therapy. The treatment switch to TAF of ETV can control renal dysfunction and reduce bone mineral density caused by TDF.en_US
dc.identifier.citationKalkan, İ.A., Karaşahin, Ö., Sarıgül, F., Toplu, S.A., Aladağ, M., Akgül, F. ve diğerleri. (2021). Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic Hepatitis B initially treated with tenofovir disoproxil: A retrospective observational survey. Hepatitis Monthly, 21(10), e118721.en_US
dc.identifier.doi10.5812/hepatmon.118721
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue10en_US
dc.identifier.scopus2-s2.0-85127217552
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://brieflands.com/articles/hepatmon-118721.html
dc.identifier.urihttps://hdl.handle.net/11468/11473
dc.identifier.volume21en_US
dc.identifier.wosWOS:000766814300002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorDemir, Yakup
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherKowsar Publicationen_US
dc.relation.ispartofHepatitis Monthly
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEntecaviren_US
dc.subjectHepatitis Ben_US
dc.subjectTenofovir Disoproxilen_US
dc.subjectTenofovir Alafenamideen_US
dc.titleComparison of tenofovir alafenamide and entecavir therapy in patients with chronic Hepatitis B initially treated with tenofovir disoproxil: A retrospective observational surveyen_US
dc.titleComparison of tenofovir alafenamide and entecavir therapy in patients with chronic Hepatitis B initially treated with tenofovir disoproxil: A retrospective observational survey
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Comparison of Tenofovir Alafenamide and Entecavir Therapy in.pdf
Boyut:
1.06 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu